Lantheus Holdings Inc
LNTH64.890USD
+0.030+0.05%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
4.30BMarktkapitalisierung
26.34KGV TTM
mehr Informationen über Lantheus Holdings Inc Unternehmen
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.
Lantheus Holdings Inc Informationen
BörsenkürzelLNTH
Name des UnternehmensLantheus Holdings Inc
IPO-datumJun 25, 2015
CEOMarkison (Brian A)
Anzahl der mitarbeiter808
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse331 Treble Cove Road
StadtNORTH BILLERICA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl01862
Telefon19786718001
Websitehttps://www.lantheus.com/
BörsenkürzelLNTH
IPO-datumJun 25, 2015
CEOMarkison (Brian A)
Führungskräfte von Lantheus Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+14285.00%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+60654.00%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-17901.00%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+2537.00%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+2141.00%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+2537.00%
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Dr. Phuong Khanh (P. K.) Morrow, M.D.
Independent Director
Independent Director
3.10K
+2537.00%
Mr. Samuel R. (Sam) Leno
Mr. Samuel R. (Sam) Leno
Independent Director
Independent Director
--
--
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Lead Independent Director
Lead Independent Director
--
--
Mr. Gary John Pruden
Mr. Gary John Pruden
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Mary Anne Heino
Ms. Mary Anne Heino
Executive Chairman of the Board, Interim Executive Officer
Executive Chairman of the Board, Interim Executive Officer
599.01K
+14285.00%
Mr. Brian A. Markison
Mr. Brian A. Markison
Chief Executive Officer, Director
Chief Executive Officer, Director
232.42K
+60654.00%
Dr. Jean-Claude Provost, M.D.
Dr. Jean-Claude Provost, M.D.
Chief Scientific Officer
Chief Scientific Officer
38.84K
-17901.00%
Dr. James H. (Jim) Thrall
Dr. James H. (Jim) Thrall
Independent Director
Independent Director
35.74K
+2537.00%
Dr. Gerard Ber, Ph.D.
Dr. Gerard Ber, Ph.D.
Independent Director
Independent Director
23.36K
+2141.00%
Ms. Minnie Baylor-Henry, J.D.
Ms. Minnie Baylor-Henry, J.D.
Independent Director
Independent Director
9.90K
+2537.00%
Umsatzaufteilung
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
240.62M
0.00%
DEFINITY
81.78M
0.00%
TechneLite
21.13M
0.00%
Neuraceq
20.44M
0.00%
Strategic partnerships and other
13.71M
0.00%
Other precision diagnostics
6.34M
0.00%
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
PYLARIFY
240.62M
0.00%
DEFINITY
81.78M
0.00%
TechneLite
21.13M
0.00%
Neuraceq
20.44M
0.00%
Strategic partnerships and other
13.71M
0.00%
Other precision diagnostics
6.34M
0.00%
Aktionärsstatistik
Aktualisiert: Sun, Jan 11
Aktualisiert: Sun, Jan 11
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.00%
Janus Henderson Investors
10.08%
The Vanguard Group, Inc.
10.06%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Andere
58.08%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
11.00%
Janus Henderson Investors
10.08%
The Vanguard Group, Inc.
10.06%
Morgan Stanley & Co. LLC
5.55%
Farallon Capital Management, L.L.C.
5.24%
Andere
58.08%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
51.50%
Investment Advisor/Hedge Fund
36.38%
Research Firm
8.68%
Hedge Fund
8.11%
Individual Investor
2.40%
Pension Fund
1.78%
Sovereign Wealth Fund
0.77%
Bank and Trust
0.72%
Family Office
0.13%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
1029
71.74M
108.19%
-15.56M
2025Q3
1018
78.96M
119.07%
-8.67M
2025Q2
1039
82.20M
120.88%
-4.84M
2025Q1
1066
83.20M
120.27%
-2.89M
2024Q4
1033
78.65M
114.86%
-4.64M
2024Q3
1003
73.69M
106.06%
-7.92M
2024Q2
959
71.82M
103.63%
-10.29M
2024Q1
912
71.21M
103.87%
-11.25M
2023Q4
868
73.50M
107.32%
-9.24M
2023Q3
828
74.80M
109.31%
-3.81M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
7.29M
11%
-208.45K
-2.78%
Sep 30, 2025
Janus Henderson Investors
6.68M
10.08%
-254.25K
-3.66%
Sep 30, 2025
The Vanguard Group, Inc.
6.92M
10.44%
+100.16K
+1.47%
Sep 30, 2025
Morgan Stanley & Co. LLC
3.68M
5.55%
+3.18M
+635.59%
Sep 30, 2025
Farallon Capital Management, L.L.C.
3.48M
5.24%
+161.00K
+4.85%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.10M
4.68%
-1.03M
-24.93%
Sep 30, 2025
State Street Investment Management (US)
2.50M
3.77%
-61.59K
-2.41%
Sep 30, 2025
Geode Capital Management, L.L.C.
1.75M
2.65%
-22.43K
-1.26%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
1.37M
2.07%
-12.04K
-0.87%
Sep 30, 2025
Reinhart Partners, LLC
1.35M
2.03%
-55.90K
-3.98%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
State Street SPDR S&P Health Care Equipment ETF
1.96%
Invesco S&P MidCap 400 GARP ETF
1.69%
First Trust Small Cap US Equity Select ETF
1.07%
VictoryShares Small Cap Free Cash Flow ETF
0.93%
Invesco S&P MidCap 400 Pure Growth ETF
0.74%
Distillate Small/Mid Cash Flow ETF
0.66%
Pacer US Small Cap Cash Cows ETF
0.56%
Gotham 1000 Value ETF
0.5%
Invesco S&P MidCap Quality ETF
0.47%
Pacer US Cash Cows Growth ETF
0.47%
Mehr Anzeigen
State Street SPDR S&P Health Care Equipment ETF
Anteil1.96%
Invesco S&P MidCap 400 GARP ETF
Anteil1.69%
First Trust Small Cap US Equity Select ETF
Anteil1.07%
VictoryShares Small Cap Free Cash Flow ETF
Anteil0.93%
Invesco S&P MidCap 400 Pure Growth ETF
Anteil0.74%
Distillate Small/Mid Cash Flow ETF
Anteil0.66%
Pacer US Small Cap Cash Cows ETF
Anteil0.56%
Gotham 1000 Value ETF
Anteil0.5%
Invesco S&P MidCap Quality ETF
Anteil0.47%
Pacer US Cash Cows Growth ETF
Anteil0.47%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
